University Hospitals

STAQ Pharma offers safety, transparency, availability, and quality to compounded medications. It features Onsite production of non-sterile to sterile solutions. And sterile-to-sterile repackaging. Inventory systems to forecast needs and proactively provide partners with critical products. It was founded in 2018 and headquartered in Denver, Colorado.

Babyscripts’ three-tiered approach to virtual maternity care allows providers to deliver risk-specific care to pregnant mothers at any time, in any place. The first tier consists of a digital education layer delivered via a mobile app, with daily gestational-age and practice-specific, customizable content extending through one year postpartum to engage and empower pregnant mothers through trusted resources. The second tier enables virtual management of pregnant patients through the addition of remote monitoring. Depending on the risk, patients are provided with medical devices (like a bluetooth-enabled blood pressure cuff) to monitor for elevated risk, alerting the provider through a unique trigger alert system to enable risk management and intervention. This smart end-to-end management of patients enables the provider to transition care outside of the clinic and address problems of access, allowing them to automate a majority of their patient care while more effectively allocating time and resources to higher-risk patients. The third tier brings the insurer into the equation in a unique collaboration between the care team and payer, solving some of the structural issues of care coordination and access to care, improving outcomes while reducing cost.

BioMotiv is a therapeutic accelerator developing a portfolio of novel medicines. BioMotiv is the mission-aligned development company of The Harrington Project for Discovery and Development. The Harrington Project, unveiled in February by University Hospitals (UH), is a first-of-its-kind $250 million initiative that promises to revolutionize how new breakthrough drugs are advanced to market. By aligning the upstream efforts of the recently created UH Case Medical Center’s Harrington Discovery Institute with the downstream development efforts of BioMotiv, The Harrington Project seeks to accelerate the therapeutic innovation process for the benefit of patients globally. The company was founded in 2012 and is headquartered in Cleveland, Ohio.

BioMotiv is a therapeutic accelerator developing a portfolio of novel medicines. BioMotiv is the mission-aligned development company of The Harrington Project for Discovery and Development. The Harrington Project, unveiled in February by University Hospitals (UH), is a first-of-its-kind $250 million initiative that promises to revolutionize how new breakthrough drugs are advanced to market. By aligning the upstream efforts of the recently created UH Case Medical Center’s Harrington Discovery Institute with the downstream development efforts of BioMotiv, The Harrington Project seeks to accelerate the therapeutic innovation process for the benefit of patients globally. The company was founded in 2012 and is headquartered in Cleveland, Ohio.